Screener
Novavax NVAX Milestones — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Novavax’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001000694-26-000018
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Sanofi licensing, royalties, and other revenue | ||||
| Licensing: | ||||
| Milestones | — | $175,000 | — | 175,000 |
| Royalties | 676 | — | 4,195 | — |
| Transition services and technology transfer: | ||||
| Upfront fee amortization(1) | 8,728 | 12,268 | 20,834 | 32,180 |
| Milestones amortization(1) | 3,762 | 5,665 | 9,313 | 14,808 |
| Cost reimbursements | 22,602 | 6,479 | 50,324 | 17,745 |
Item 1. Consolidated Financial Statements
FAQ
- What is Novavax's milestones — total revenue?
- Novavax (NVAX) reported milestones — total revenue of $0 in Q2 2026.
- How has Novavax's milestones — total revenue changed year-over-year?
- Novavax's milestones — total revenue decreased by 100.0% year-over-year, from $175M to $0.
- What does milestones — total revenue mean?
- This metric represents the total revenue recognized from milestone payments associated with licensing agreements, research collaborations, or commercial partnerships. It reflects the successful achievement of specific clinical, regulatory, or commercial development targets defined within contractual arrangements. Tracking this revenue stream provides insight into the company's ability to monetize its intellectual property and development pipeline through external partnerships.
Ask your AI about Novavax's milestones — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude